You are here

  • Home
  • Archive
  • Volume 9, Issue 1
  • Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)

 

Online download statistics by month:

Online download statistics by month: January 2021 to July 2025

AbstractFullPdf
Jan 202124324581
Feb 202121221350
Mar 2021848421
Apr 2021686821
May 202110210218
Jun 202112812822
Jul 202110910923
Aug 2021868617
Sep 2021818123
Oct 2021767635
Nov 2021999927
Dec 2021969618
Jan 2022798528
Feb 2022747518
Mar 20229810335
Apr 2022858921
May 2022899324
Jun 2022838931
Jul 2022717518
Aug 2022818113
Sep 202210010333
Oct 2022565714
Nov 2022505122
Dec 2022474910
Jan 2023666611
Feb 2023515419
Mar 2023555622
Apr 2023434714
May 2023484911
Jun 2023575911
Jul 2023747417
Aug 202349496
Sep 2023404014
Oct 2023454523
Nov 2023575715
Dec 2023616216
Jan 202426278
Feb 2024636314
Mar 2024626366
Apr 2024555525
May 2024545415
Jun 2024575817
Jul 2024606125
Aug 2024414054
Sep 2024313119
Oct 2024454723
Nov 2024666915
Dec 2024444517
Jan 2025424223
Feb 202511411413
Mar 2025373820
Apr 202511011160
May 2025394021
Jun 2025515137
Jul 2025110
Total394140051274